DK2292584T3 - Farmaceutisk sammensætning omfattende levalbuterol L-hemitartratsalt som aerosolformulering - Google Patents
Farmaceutisk sammensætning omfattende levalbuterol L-hemitartratsalt som aerosolformulering Download PDFInfo
- Publication number
- DK2292584T3 DK2292584T3 DK10176026.2T DK10176026T DK2292584T3 DK 2292584 T3 DK2292584 T3 DK 2292584T3 DK 10176026 T DK10176026 T DK 10176026T DK 2292584 T3 DK2292584 T3 DK 2292584T3
- Authority
- DK
- Denmark
- Prior art keywords
- levalbuterol
- pharmaceutical composition
- ethanol
- aerosol formulation
- tartrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/30—Materials not provided for elsewhere for aerosols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0484—Alcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0488—Surfactant, e.g. for the lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Claims (13)
1. Farmaceutisk sammensætning omfattende levalbuterol L-hemitartrat og en farmaceutisk acceptabel bærer, hvor sammensætningen er en aerosolformulering tilpasset til indgivelse under anvendelse af en inhalator med afmålt dosis, hvor aerosolformuleringen omfatter levalbuterol L-hemitartrat i krystallinsk form og et drivmiddel.
2. Farmaceutisk sammensætning ifølge krav 1, hvor drivmidlet er 1,1,1,2-tetrafluorethan.
3. Farmaceutisk sammensætning ifølge krav 1 eller 2, hvor aerosolformuleringen yderligere omfatter et overfladeaktivt stof.
4. Farmaceutisk sammensætning ifølge krav 3, hvor det overfladeaktive stof er oliesyre.
5. Farmaceutisk sammensætning ifølge et af kravene 1 til 4, hvor aerosolformuleringen yderligere omfatter et hjælpeopløsningsmiddel.
6. Farmaceutisk sammensætning ifølge krav 5, hvor hjælpeopløsningsmidlet er ethanol.
7. Farmaceutisk sammensætning ifølge krav 6, hvor ethanolen er dehydreret ethanol.
8. Farmaceutisk sammensætning ifølge krav 1, som er tilpasset til indgivelse af en dosis på fra 25 pg til 120 pg levalbuterol til et menneske, hvor dosen er beregnet som den frie base.
9. Farmaceutisk sammensætning ifølge krav 8, som er tilpasset til indgivelse af en dosis på 45 pg eller 90 pg levalbuterol til et menneske, hvor dosen er kalkuleret som den frie base.
10. Farmaceutisk sammensætning ifølge krav 1, hvor aerosolformuleringen omfatter levalbuterol L-hemitartrat i krystallinsk form, 1,1,1,2-tetrafluorethan, oliesyre og ethanol.
11. Farmaceutisk sammensætning ifølge krav 10, hvor ethanolen er dehydreret ethanol.
12. Farmaceutisk sammensætning ifølge krav 1, hvor et gram af sammensætningen indeholder 1,04 mg mikroniseret levalbuterol L-hemitartrat, 0,951 g 1,1,1,2-tetrafluorethan, 0,0521 mg oliesyre og 0,0476 g dehydreret ethanol, og hvor aerosolformuleringen foreligger i form af en suspension.
13. Farmaceutisk sammensætning ifølge krav 1, hvor et gram af sammensætningen indeholder 2,08 mg mikroniseret levalbuterol L-hemitartrat, 0,950 g 1,1,1,2-tetrafluorethan, 0,104 mg oliesyre og 0,0475 g dehydreret ethanol, og hvor aerosolformuleringen foreligger i form af en suspension.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43219502P | 2002-12-10 | 2002-12-10 | |
EP06110646.4A EP1671942B2 (en) | 2002-12-10 | 2003-12-08 | Aerosol formulation comprising levalbuterol L-tartrate salt |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2292584T3 true DK2292584T3 (da) | 2017-05-01 |
Family
ID=32507867
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10176026.2T DK2292584T3 (da) | 2002-12-10 | 2003-12-08 | Farmaceutisk sammensætning omfattende levalbuterol L-hemitartratsalt som aerosolformulering |
DK06110646.4T DK1671942T4 (da) | 2002-12-10 | 2003-12-08 | Aerosolformulering omfattende levalbuterol L-tartratsalt |
DK03786896T DK1572622T3 (da) | 2002-12-10 | 2003-12-08 | Anvendelse af levalbuterol-L-tartrat ved fremstilling af en doseringsinhalator |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06110646.4T DK1671942T4 (da) | 2002-12-10 | 2003-12-08 | Aerosolformulering omfattende levalbuterol L-tartratsalt |
DK03786896T DK1572622T3 (da) | 2002-12-10 | 2003-12-08 | Anvendelse af levalbuterol-L-tartrat ved fremstilling af en doseringsinhalator |
Country Status (19)
Country | Link |
---|---|
US (8) | US7256310B2 (da) |
EP (3) | EP2292584B1 (da) |
JP (1) | JP4570960B2 (da) |
KR (3) | KR20050088307A (da) |
AT (2) | ATE324364T1 (da) |
AU (1) | AU2003295695B2 (da) |
CA (1) | CA2507572C (da) |
CY (2) | CY1106315T1 (da) |
DE (2) | DE60336089D1 (da) |
DK (3) | DK2292584T3 (da) |
ES (3) | ES2626648T3 (da) |
IL (2) | IL168739A (da) |
MX (1) | MXPA05006087A (da) |
NO (1) | NO331649B1 (da) |
NZ (1) | NZ541168A (da) |
PL (1) | PL212725B1 (da) |
PT (3) | PT1572622E (da) |
SI (2) | SI1572622T1 (da) |
WO (1) | WO2004052835A1 (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6466862B1 (en) * | 1999-04-19 | 2002-10-15 | Bruce DeKock | System for providing traffic information |
EA200700600A1 (ru) * | 2004-09-09 | 2008-02-28 | Сипла Лимитед | Фармацевтическая композиция, содержащая изомер бета-миметического агента и антихолинергический агент |
WO2006064283A1 (en) | 2004-12-17 | 2006-06-22 | Cipla Limited | Pharmaceutical compounds and compositions |
RU2440972C2 (ru) | 2004-12-17 | 2012-01-27 | Сипла Лимитед | Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его |
US8542097B2 (en) | 2011-04-13 | 2013-09-24 | Jingle Technologies Llc | Systems and methods for transmitting information, alerts, and/or comments to participants based on location information |
EP3042892A1 (en) | 2015-01-09 | 2016-07-13 | Deva Holding Anonim Sirketi | Amorphisation of levosalbutamol tartrate |
CN106727318A (zh) * | 2016-12-22 | 2017-05-31 | 山东京卫制药有限公司 | 一种气雾剂及其制备方法 |
US20210290568A1 (en) * | 2020-03-19 | 2021-09-23 | Cai Gu Huang | Inhalable formulation of a solution containing levalbuterol tartrate |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1200886A (en) * | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8828477D0 (en) † | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5776434A (en) | 1988-12-06 | 1998-07-07 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5345980A (en) | 1989-09-21 | 1994-09-13 | Glaxo Group Limited | Method and apparatus an aerosol container |
US5362755A (en) | 1990-01-05 | 1994-11-08 | Sepracor, Inc. | Method for treating asthma using optically pure (R)-albuterol |
US5255183A (en) * | 1990-05-29 | 1993-10-19 | Interactive Voice Data System Inc. | Telephone-based personnel tracking system |
EP0587790B2 (en) | 1991-06-10 | 2000-03-08 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
DE69233319T2 (de) | 1991-12-18 | 2005-02-17 | Minnesota Mining & Manufacturing Company, St. Paul | Aerosolzusammensetzungen für Arzneimittelsuspensionen |
US5399765A (en) | 1994-05-23 | 1995-03-21 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
US5545745A (en) * | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
EE03997B1 (et) * | 1995-04-14 | 2003-04-15 | Glaxo Wellcome Inc. | Albuterooli doseeriv inhalaator |
US5603918A (en) | 1995-06-09 | 1997-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aerosol composition of a salt of ipratropium and a salt of albuterol |
US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
GB9806462D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Improved compositions for inhalation |
ES2234266T3 (es) * | 1998-07-24 | 2005-06-16 | Jago Research Ag | Formulaciones medicas para aerosoles. |
DE59904648D1 (de) * | 1998-08-04 | 2003-04-24 | Jago Res Ag Muttenz | Medizinische aerosolformulierungen |
CZ303154B6 (cs) * | 1998-11-13 | 2012-05-09 | Jagotec Ag | Suchá prášková formulace k inhalaci obsahující stearát horecnatý |
CN1173929C (zh) | 1999-10-19 | 2004-11-03 | 中国科学院成都有机化学研究所 | 光学纯肾上腺素类β-激动剂的组合拆分制备法 |
US6451289B2 (en) | 2000-03-24 | 2002-09-17 | Sepracor Inc. | Albuterol formulations |
GB0030171D0 (en) | 2000-12-11 | 2001-01-24 | Cipla Ltd | Process for preparing isomers of salbutamol |
PL207377B1 (pl) * | 2001-03-30 | 2010-12-31 | Jagotec Ag | Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie |
CN1206205C (zh) * | 2001-04-26 | 2005-06-15 | 中国科学院成都有机化学研究所 | R-沙丁胺醇酒石酸盐的制备方法 |
DE10120531A1 (de) * | 2001-04-26 | 2002-10-31 | Basf Ag | Neue Reaktivfarbstoffe und deren Verwendung zum Färben von Substraten, welche nucleophile Gruppen enthalten |
-
2003
- 2003-12-08 PL PL377336A patent/PL212725B1/pl unknown
- 2003-12-08 AU AU2003295695A patent/AU2003295695B2/en not_active Expired
- 2003-12-08 ES ES10176026.2T patent/ES2626648T3/es not_active Expired - Lifetime
- 2003-12-08 WO PCT/US2003/037079 patent/WO2004052835A1/en active Application Filing
- 2003-12-08 JP JP2004559144A patent/JP4570960B2/ja not_active Expired - Fee Related
- 2003-12-08 DK DK10176026.2T patent/DK2292584T3/da active
- 2003-12-08 SI SI200330331T patent/SI1572622T1/sl unknown
- 2003-12-08 PT PT03786896T patent/PT1572622E/pt unknown
- 2003-12-08 NZ NZ541168A patent/NZ541168A/en not_active IP Right Cessation
- 2003-12-08 AT AT03786896T patent/ATE324364T1/de active
- 2003-12-08 DE DE60336089T patent/DE60336089D1/de not_active Expired - Lifetime
- 2003-12-08 PT PT06110646T patent/PT1671942E/pt unknown
- 2003-12-08 DE DE60304900T patent/DE60304900T2/de not_active Expired - Lifetime
- 2003-12-08 CA CA2507572A patent/CA2507572C/en not_active Expired - Lifetime
- 2003-12-08 KR KR1020057010435A patent/KR20050088307A/ko not_active Application Discontinuation
- 2003-12-08 SI SI200331954T patent/SI1671942T2/sl unknown
- 2003-12-08 EP EP10176026.2A patent/EP2292584B1/en not_active Expired - Lifetime
- 2003-12-08 KR KR1020087028024A patent/KR101166955B1/ko active IP Right Grant
- 2003-12-08 ES ES03786896T patent/ES2263051T3/es not_active Expired - Lifetime
- 2003-12-08 MX MXPA05006087A patent/MXPA05006087A/es active IP Right Grant
- 2003-12-08 EP EP06110646.4A patent/EP1671942B2/en not_active Expired - Lifetime
- 2003-12-08 PT PT101760262T patent/PT2292584T/pt unknown
- 2003-12-08 ES ES06110646.4T patent/ES2361172T5/es not_active Expired - Lifetime
- 2003-12-08 AT AT06110646T patent/ATE498604T1/de active
- 2003-12-08 KR KR1020107014278A patent/KR20100080865A/ko not_active Application Discontinuation
- 2003-12-08 DK DK06110646.4T patent/DK1671942T4/da active
- 2003-12-08 EP EP03786896A patent/EP1572622B1/en not_active Expired - Lifetime
- 2003-12-08 US US10/728,873 patent/US7256310B2/en active Active
- 2003-12-08 DK DK03786896T patent/DK1572622T3/da active
-
2005
- 2005-05-23 IL IL168739A patent/IL168739A/en active IP Right Grant
- 2005-07-08 NO NO20053339A patent/NO331649B1/no not_active IP Right Cessation
-
2006
- 2006-07-03 CY CY20061100912T patent/CY1106315T1/el unknown
-
2007
- 2007-08-08 US US11/891,048 patent/US20080119564A1/en not_active Abandoned
-
2010
- 2010-07-09 US US12/833,882 patent/US20100272654A1/en not_active Abandoned
-
2011
- 2011-03-11 CY CY20111100273T patent/CY1111330T1/el unknown
- 2011-04-14 IL IL212369A patent/IL212369A/en active IP Right Grant
-
2012
- 2012-10-02 US US13/633,801 patent/US20130028845A1/en not_active Abandoned
-
2013
- 2013-04-29 US US13/873,084 patent/US8765153B2/en not_active Expired - Lifetime
-
2014
- 2014-05-21 US US14/283,754 patent/US20150071969A1/en not_active Abandoned
-
2016
- 2016-01-22 US US15/003,883 patent/US20160368858A1/en not_active Abandoned
-
2017
- 2017-10-18 US US15/786,917 patent/US20180222845A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8765153B2 (en) | Levalbuterol salt | |
KR20120092163A (ko) | 무스카린성 수용체 길항제 및 베타-2 아드레날린 수용체 효능제의 조합물 | |
KR20110096545A (ko) | 흡입용 건조 분말 의약 조성물 | |
JP2006509802A5 (da) | ||
WO2010097114A1 (en) | Novel combination of therapeutic agents | |
EP1494648B1 (en) | Powder formulations suitable for inhalation |